Last reviewed · How we verify
low dose capecitabine
Capecitabine is a prodrug that is converted into 5-fluorouracil, which inhibits thymidylate synthase and disrupts DNA synthesis in cancer cells.
Capecitabine is a prodrug that is converted into 5-fluorouracil, which inhibits thymidylate synthase and disrupts DNA synthesis in cancer cells. Used for Adjuvant treatment of Dukes' C and D colon cancer, Monotherapy for treatment of advanced colorectal cancer, Adjuvant treatment of stage III (Dukes' C) colon cancer.
At a glance
| Generic name | low dose capecitabine |
|---|---|
| Also known as | Xeloda |
| Sponsor | Lund University Hospital |
| Drug class | Antimetabolite |
| Target | Thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This leads to cell cycle arrest and apoptosis in rapidly dividing cancer cells. The inhibition of thymidylate synthase also reduces the production of thymidine, a nucleotide required for DNA synthesis.
Approved indications
- Adjuvant treatment of Dukes' C and D colon cancer
- Monotherapy for treatment of advanced colorectal cancer
- Adjuvant treatment of stage III (Dukes' C) colon cancer
- Monotherapy for treatment of metastatic colorectal cancer
Common side effects
- Hand-foot syndrome
- Diarrhea
- Nausea
- Vomiting
- Fatigue
- Neutropenia
- Anemia
- Thrombocytopenia
Key clinical trials
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) (PHASE2, PHASE3)
- Next Generation STAR-TREC (NG-ST) - Organ Preservation in Early Rectal Cancer (PHASE4)
- Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer (PHASE3)
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (PHASE1, PHASE2)
- Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) (PHASE2)
- A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) (PHASE3)
- Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- low dose capecitabine CI brief — competitive landscape report
- low dose capecitabine updates RSS · CI watch RSS
- Lund University Hospital portfolio CI